UGA researchers develop sustainable way to manufacture important drug precursors

February 25, 2014

Print
Share    
Writer:
James Hataway

James Hataway

PR Coordinator

Recent and archived articles by James Hataway

OVPR
Research, Office of the Vice President for (OVPR)
Work: 706-542-5222
Email:


Related Sites

Athens, Ga. - Researchers at the University of Georgia have found a new way to manufacture an important molecule used in the pharmaceutical industry to create anticoagulants, a class of drug commonly prescribed to treat or prevent abnormal blood clots that can lead to heart attack, stroke and deep vein thrombosis.

The molecule 4 hydroxycoumarin, or 4HC, is currently produced through chemical synthesis using petroleum-based products, which can create harmful residues and, due to the rapid depletion of natural resources, may not suffice as a long-term manufacturing technique.

"This biological process we have developed uses no petroleum and it produces no harmful byproducts," said Yuheng Lin, lead author of the paper describing the process in Nature Communications and doctoral candidate in the UGA College of Engineering. "The 4HC we can create in the lab is also perfectly suited to create anticoagulants like warfarin."

The precise number of people who develop obstructed blood vessels, or thromboembolisms, is difficult to determine, but estimates range from 300,000 to 600,000 per year in the U.S. alone, according to the Centers for Disease Control and Prevention. Between 60,000 and 100,000 of patients who suffer from thromboembolisms die very soon afterward, and many more are left with significant disabilities as a result of the trauma.

Although warfarin was approved for use as a medication 60 years ago, it remains one of the most popular and effective methods of treating these dangerous blood clots.

"This is a very important class of drugs, and we hope our research will make its production easier and less expensive," said Yajun Yan, principal investigator for the project and assistant professor in the College of Engineering. "Lower production costs will ultimately result in cheaper medications for patients."

The technique uses a strain of E. coli, a harmless, widely studied bacteria used by research scientists and biological engineers, to turn simple sugars into the more complex molecules required to manufacture the anticoagulants. While their current experiments are small in scale, the researchers believe it could be easily expanded to suit industrial needs.

"We also believe that our technique could be used to manufacture other pharmaceuticals and industrial products," Lin said.

The researchers have used similar processes to produce salicylic acid, an important chemical used to produce aspirin and a variety of skin care products.

"UGA is currently seeking partners interested in licensing the technology and also partnering with professor Yan toward the development of industrial uses for the invention," said Gennaro Gama, senior technology licensing manager at UGA. "We believe this technology is a promising new method to produce a variety of useful commodities."

For licensing information, contact Gennaro Gama, gjg@uga.edu or 706-583-8088.

 

Filed under: Medical Science, Health Sciences, Pharmaceuticals

News Service

Director
Cynthia Hoke

706 / 542-8083
Public Relations Coordinator
Stephanie Schupska

706 / 542-6927
Public Relations Coordinator
Sara Freeland

706 / 542-8077
Science Writer
April Sorrow

706 / 542-7991

Broadcast, Video and Photography

Director
Steve Bell

706 / 542-8089
Broadcast Coordinator
Pete Konenkamp

706 / 542-8080
Photography
Rick O‘Quinn

706 / 542-8085